Sanofi Suffers Second Clinical Setback For Venglustat
Fails In Rare Genetic Kidney Disease Trial
The French drugmaker has halted a pivotal trial of venglustat in autosomal dominant polycystic kidney disease, a few months after the drug failed as a treatment for Parkinson’s disease. Sanofi will go back to focusing on the therapy's potential in lysosomal storage diseases.
You may also be interested in...
As Biogen makes history in Alzheimer’s, Bayer is aiming for a breakthrough in Parkinson’s, another major target in neuroscience.
Dupixent was Sanofi’s top-selling product in 2020, but its vaccines division also saw significant growth in the year led by its differentiated influenza vaccines, which helped drive the big pharma’s business during the year, accompanied by significant cost savings.
Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.